Search results
Showing 361 to 375 of 379 results for lung cancer
The NGAL Test for early diagnosis of acute kidney injury (MIB3)
NICE has developed a medtech innovation briefing (MIB) on the NGAL Test for early diagnosis of acute kidney injury .
immunosuppression• obesity• hypertension• chronic lung disease• cardiovascular disease• cerebrovascular disease• active...
What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?
immunosuppression• obesity• hypertension• chronic lung disease• cardiovascular disease• cerebrovascular disease• active...
This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE
Faster, fairer access to HealthTech under new national programme
People across England and Wales are set to receive faster, fairer access to innovative HealthTech under the new National HealthTech Access Programme (NHAP).
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE.
Over 500 people a year can access a new life extending lung cancer treatment
An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.
More than 400 people could benefit from life-extending advanced lung cancer treatment
Durvalumab recommended as an option for treating non-small-cell lung cancer.
Over 700 people a year could benefit from a new lung cancer drug
An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC) has been recommended by NICE and will be available to patients from today (Thursday, 14 April).
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer
For the first time, we have recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce the risk of the disease coming back.
NICE Board says new method allowing greater weight to be given to severe diseases is working
At today's meeting (25th September 2024) our board has concluded that the new severity modifier is working as intended.
We have also recommended osimertinib for routine use on the NHS today.
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
Additional evidence needed to assess histology-independent cancer drugs
A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.